Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Sept. 23, 2024 /PRNewswire/ - ...

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

Core Viewpoint - DexCom, Inc. experienced a significant stock price decline following the announcement of its second quarter financial results for fiscal 2024 and a reduction in revenue guidance for the full fiscal year 2024, attributed to unmet strategic initiatives [1][2]. Group 1: Financial Performance - On July 25, 2024, DexCom announced its second quarter financial results and lowered its revenue guidance for the full fiscal year 2024 [1]. - The company's stock price fell from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in just one day [1]. Group 2: Legal Action - Shareholders who purchased shares of DexCom during the class period from January 8, 2024, to July 25, 2024, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 21, 2024 [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and July 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form ...

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=103503&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=103185&from=3 CLASS PERIOD: January 8, 2024 to J ...

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its business performance and growth prospects during the Class Period from January 8, 2024, to July 25, 2024 [1][2]. Group 1: Allegations Against DexCom - The complaint claims that DexCom's statements about growth and anticipated margins were overly optimistic, primarily due to reliance on attracting new customers [2]. - It is alleged that DexCom faced challenges in maintaining successful existing distribution channels [2]. - As a result, the statements made by DexCom regarding its business operations and future prospects were materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to apply to be appointed as a lead plaintiff representative for the class [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected DexCom investors to contact them for more information [4][5]. - The firm has a strong reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].